Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595829 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00595829 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 3 participants.
The verdict
NCT00595829, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
Interventions
- DRUG XL019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595829
The ClinicalTrials.gov registry entry for NCT00595829 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL019 is the first listed.
NCT00595829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00595829 about?
NCT00595829 is a clinical study titled "A Phase 1 Study of XL019 in Adults With Polycythemia Vera". The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
What is the current status of trial NCT00595829?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2007-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00595829?
The interventions under investigation include: XL019 (DRUG).
Who is sponsoring clinical trial NCT00595829?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.